Voyager Therapeutics

General Information
Business:

We are a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system, or CNS. We focus on CNS diseases where we believe that an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. We have created a product engine that enables us to engineer, optimize, manufacture and deliver our AAV-based therapies that have the potential to provide durable efficacy following a single administration directly to the CNS. Our product engine has rapidly generated programs for five CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis, or a form of the disease caused by a single gene mutation; Friedreich’s ataxia; Huntington’s disease; and spinal muscular atrophy.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES
Employees: 48
Founded: 2012
Contact Information
Address 75 Sidney Street, Cambridge, MA 02139, US
Phone Number (857) 259-5340
Web Address http://www.voyagertherapeutics.com
View Prospectus: Voyager Therapeutics
Financial Information
Market Cap $364mil
Revenues $7.5 mil (last 12 months)
Net Income $-27.2 mil (last 12 months)
IPO Profile
Symbol VYGR
Exchange NASDAQ
Shares (millions): 5.0
Price range $14.00 - $14.00
Est. $ Volume $70.0 mil
Manager / Joint Managers Cowen and Company/ Piper Jaffray/ Wedbush PacGrow/ Nomura
CO-Managers -
Expected To Trade: 11/11/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change